Clinical Trial Search

Primary: Percent of Ablation Targets With Termination of the Clinical Ventricular Arrhythmia After RF Energy Delivery — 20 Participants

Primary: Number of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT) — 16; 29 Participants

Primary: Percentage of Participants Free From VT at 1 Year Post-Treatment — 62 percentage of participants free from VT

Primary: Ventricular Tachycardia - Incidence of Ventricular Tachycardia on Inpatient Telemetry Monitoring — 7; 4 Participants

Primary: Number of Participants With Recurrence of Ventricular Tachycardia — 13; 13 Participants

Primary: Number of Electrocardiograms (ECGs) Collected — 77; 67; 53 ECG

Primary: The Percentage of Subjects That Expire From All-cause Mortality Within 12-months Post Ablation. — 13.3 percentage of mortality

Primary: ICD (Implantable Cardioverter Defibrillator) Shock Free Survival — 1 Participants

Primary: Number of Participants With Procedural Success — 8; 6 Participants

Primary: Number of Participants With Transient Ischemic Attack — 6; 22 participants — p=0.001

Primary: Number of Serious Adverse Events — 2; 0; 0; 1 Events

Primary: Electrogram Duration at Digital Twin Predicted Sites Compared to Non-predicted Sites — 77.5; 65.7 ms

Primary: Number of Participants With Ventricular Tachycardia Inducibility — 6 Participants

Primary: Number of Patients With Ventricular Ectopy or VT During Exercise Treadmill Testing — 2; 9 Participants — p=0.008

Primary: Inhibition of Idiopathic Ventricular Tachycardia

Primary: The Maximum Reduction in Ventricular Rate, Measured on Holter Monitoring, Within 60 Minutes From Drug Administration. — 135.5; 130.3; 130.7; 95.2 bpm — p=<0.0001

Primary: Number of Ventricular Ectopic Beats (VEBs) Per Day — 2685; 677 number of VEBs per day — p=<0.0001

Primary: Percentage of Intrinsic Ventricular Events — 82.7; 22.8 % of intrinsic ventricular events — p=<0.0001

Primary: Endothelial Function Assessed by Flow Mediated Vasodilatation — 1.96; 1.73 EndoPAT index (EnFI)

Primary: Number of Participants Who Had Inducible Ventricular Tachycardia Under General Anesthesia. — 7; 5; 5 participants

Primary: Number of Participants With Freedom From Device-and Procedure-related Adverse Events and Serious Adverse Events — 71; 14; 85; 83 Participants

Primary: Comparison of the Percentage of Patients With Scar in Each Segment as Determined by MIBG SPECT Versus Electroanatomic at Baseline — 2; 4; 1; 4 Participants

Primary: Freedom From Recurrent VT, Cardiovascular Rehospitalization, and All-cause Mortality — 33; 25; 28; 27 Participants

Primary: Number of Participants With Technical Success — 5 Participants

Primary: Number of Subjects With Operative and Post-operative Serious Adverse Events — 4; 1 participants

Primary: Number of Subjects Without Hospitalization for Ventricular Tachycardia (VT) During 6 Months — 38 Participants

Primary: Number of Ventricular Ectopic Beats Recorded During Exercise (and Recovery) — 46; 0 number of ventricular beats

Primary: Peak Vo2 — 33; 12.5 ml/kg/min

Primary: Percentage of Subjects Classified as "Not Worsened" for Changes in the Minnesota Living With Heart Failure Questionnaire and Six-minute Walk Distance Between Periods of…

Primary: Time to Event Analysis: Number of Patients Who Experienced the First Cardiovascular Hospitalization Within 2 Years Post-implant — 43; 40 number of participants — p=0.72